
    
      Two full pharmacokinetic (PK) measurements will be performed. Samples collected will include:
      plasma for estradiol (E2), emtricitabine (FTC), tenofovir (TFV), and tenofovir alafenamide
      (TAF) measurement; and peripheral blood mononuclear cells (PBMC) for
      emtricitabine-triphosphate (FTC-TP) and tenofovir-diphosphate (TFV-DP) intracellular
      quantification.
    
  